Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting.

Jönsson AK, Spigset O, Reis M.

Ther Drug Monit. 2019 Jun;41(3):348-356. doi: 10.1097/FTD.0000000000000585.

PMID:
31025986
2.

Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence.

Jönsson AK, Schill J, Olsson H, Spigset O, Hägg S.

CNS Drugs. 2018 Jan;32(1):47-64. doi: 10.1007/s40263-018-0495-7. Review.

3.

Comparing Methods for Estimating Direct Costs of Adverse Drug Events.

Gyllensten H, Jönsson AK, Hakkarainen KM, Svensson S, Hägg S, Rehnberg C.

Value Health. 2017 Dec;20(10):1299-1310. doi: 10.1016/j.jval.2017.06.007. Epub 2017 Jul 25.

4.

Increased Risk of Drug-Induced Hyponatremia during High Temperatures.

Jönsson AK, Lövborg H, Lohr W, Ekman B, Rocklöv J.

Int J Environ Res Public Health. 2017 Jul 22;14(7). pii: E827. doi: 10.3390/ijerph14070827.

5.

Reference values of lithium in postmortem femoral blood.

Söderberg C, Wernvik E, Jönsson AK, Druid H.

Forensic Sci Int. 2017 Aug;277:207-214. doi: 10.1016/j.forsciint.2017.06.007. Epub 2017 Jun 15.

PMID:
28654858
6.

Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers.

Natanaelsson J, Hakkarainen KM, Hägg S, Andersson Sundell K, Petzold M, Rehnberg C, Jönsson AK, Gyllensten H.

Res Social Adm Pharm. 2017 Nov;13(6):1151-1158. doi: 10.1016/j.sapharm.2016.11.008. Epub 2016 Nov 19.

PMID:
27894838
7.

Risk Factors for Fatal Hyperglycaemia Confirmed by Forensic Postmortem Examination - A Nationwide Cohort in Sweden.

Walz L, Jönsson AK, Zilg B, Östgren CJ, Druid H.

PLoS One. 2016 Oct 21;11(10):e0164950. doi: 10.1371/journal.pone.0164950. eCollection 2016.

8.

Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study.

Mårdby AC, Schiöler L, Sundell KA, Bjerkeli P, Lesén E, Jönsson AK.

Eur J Clin Pharmacol. 2016 Nov;72(11):1381-1389. Epub 2016 Aug 3.

PMID:
27488388
9.

Antipsychotics - Postmortem fatal and non-fatal reference concentrations.

Söderberg C, Wernvik E, Tillmar A, Spigset O, Kronstrand R, Reis M, Jönsson AK, Druid H.

Forensic Sci Int. 2016 Sep;266:91-101. doi: 10.1016/j.forsciint.2016.05.002. Epub 2016 May 10.

PMID:
27236367
10.

Refill Adherence in Relation to Substitution and the Use of Multiple Medications: A Nationwide Population Based Study on New ACE-Inhibitor Users.

Bjerkeli PJ, Jönsson AK, Lesén E, Mårdby AC, Sundell KA.

PLoS One. 2016 May 18;11(5):e0155465. doi: 10.1371/journal.pone.0155465. eCollection 2016.

11.

Non-prescribed use of psychoactive prescription drugs among drug-impaired drivers in Sweden.

Tjäderborn M, Jönsson AK, Sandström TZ, Ahlner J, Hägg S.

Drug Alcohol Depend. 2016 Apr 1;161:77-85. doi: 10.1016/j.drugalcdep.2016.01.031. Epub 2016 Feb 6.

12.

Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study.

Hedna K, Hakkarainen KM, Gyllensten H, Jönsson AK, Petzold M, Hägg S.

Eur J Clin Pharmacol. 2015 Dec;71(12):1525-33. doi: 10.1007/s00228-015-1950-8. Epub 2015 Sep 26.

13.

Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?

Hedna K, Hakkarainen KM, Gyllensten H, Jönsson AK, Andersson Sundell K, Petzold M, Hägg S.

PLoS One. 2015 Sep 11;10(9):e0137451. doi: 10.1371/journal.pone.0137451. eCollection 2015.

14.

The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.

Karlsson SA, Jacobsson I, Boman MD, Hakkarainen KM, Lövborg H, Hägg S, Jönsson AK.

Eur J Clin Pharmacol. 2015 May;71(5):631-6. doi: 10.1007/s00228-015-1839-6. Epub 2015 Apr 7.

15.

Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults.

Gyllensten H, Hakkarainen KM, Hägg S, Carlsten A, Petzold M, Rehnberg C, Jönsson AK.

PLoS One. 2014 Mar 17;9(3):e92061. doi: 10.1371/journal.pone.0092061. eCollection 2014.

16.

Prevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults.

Hakkarainen KM, Gyllensten H, Jönsson AK, Andersson Sundell K, Petzold M, Hägg S.

Br J Clin Pharmacol. 2014 Jul;78(1):170-83. doi: 10.1111/bcp.12314.

17.

Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey.

Gyllensten H, Rehnberg C, Jönsson AK, Petzold M, Carlsten A, Andersson Sundell K.

BMJ Open. 2013 Jun 20;3(6). pii: e002574. doi: 10.1136/bmjopen-2013-002574.

18.

Is the level of patient co-payment for medicines associated with refill adherence in Sweden?

Lesén E, Andersson Sundell K, Carlsten A, Mårdby AC, Jönsson AK.

Eur J Public Health. 2014 Feb;24(1):85-90. doi: 10.1093/eurpub/ckt062. Epub 2013 Jun 6.

PMID:
23748594
19.

Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.

Jönsson AK, Spigset O, Hägg S.

CNS Drugs. 2012 Aug 1;26(8):649-62. doi: 10.2165/11633920-000000000-00000. Review.

PMID:
22731933
20.

A fatal outcome after unintentional overdosing of rivastigmine patches.

Lövborg H, Jönsson AK, Hägg S.

Curr Drug Saf. 2012 Feb;7(1):30-2.

Supplemental Content

Loading ...
Support Center